Heron Therapeutics, Inc. · NASDAQ:HRTX
Heron Therapeutics — Investor Presentation (November 2017)
18 slides from Heron Therapeutics's investor presentation, Nov 9, 2017
Slide 1: Corporate Presentation November 9, 2017
Corporate Presentation November 9, 2017 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation, and
Slide 3: CINVANTI Now Approved
CINVANTI™ Now Approved CINVANTI™ is the first and only polysorbate 80-free IV NK1 receptor antagonist approved for the prevention of both acute and delayed CINV CINVANTI™ is indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting
Slide 4: CINV Prophylaxis Requires Two Complimentary Mechanisms of Action
CINV Prophylaxis Requires Two Complimentary Mechanisms of Action NK1 receptor antagonists EMEND® IV (fosaprepitant) has 90% share of the US NK1 market Infusion site reactions (predominately infusion site pain) observed with EMEND® IV are believed to be caused by the surfactant polysorbate 80 in the
Slide 5: The Goal of Antiemetic Therapy is to Prevent CINV Across Both Acute and Delayed Phases
The Goal of Antiemetic Therapy is to Prevent CINV Across Both Acute and Delayed Phases Acute Delayed Neurotransmitters Involved 5-HT3 NK1 NK1 5-HT3 5-HT3 and NK1 pathways are important in both acute and delayed phases of CINV Martin 1996; Grundberg 2004 Patterns of CINV and Neurotransmitters Involve
Slide 6: Heron Is the Only Company with Two Single-Agent Products Approved for CINV
Cisplatin Cyclophosphamide/carboplatin Acute phase Delayed phase Intensity of Emesis 0 1 2 3 4 5 Days Heron Therapeutics Is the Only Company with Two Single-Agent Products Approved for Prevention of Acute and Delayed CINV NK1 5-HT3
Slide 7: Despite an NCCN Category Recommendation, NK1's are Underutilized
Despite an NCCN Category 1 Recommendation, NK1’s are Underutilized Percent of Patients Receiving NK1 Therapy HEC 5-HT3 dexamethasone NK1 olanzapine 5-HT3 dexamethasone NK1 olanzapine MEC NCCN Antiemetic Guidelines IPSOS “US Tandem Oncology Monitor Anti-Emetics Report” is based on chart audit data of
Slide 8: Aprepitant Has Provided Unsurpassed Efficacy for CINV Prevention for Nearly 15 Years
Aprepitant Has Provided Unsurpassed Efficacy for CINV Prevention for Nearly 15 Years FDA approved 2003 NCCN Category 1 recommendation Yes Phase 3/4 clinical trials* 22 Patients studied in clinical trials* 7100+ ~1.4 million administrations per year*^ ~90% of which is IV fosaprepitant Aprepitant is t
Slide 9: Polysorbate Is a Synthetic Surfactant Associated with Adverse Events
Polysorbate 80 Is a Synthetic Surfactant Associated with Adverse Events Reactions related to PS-80 Injectable drugs containing PS-80 Chemotherapy Supportive Care Cabazitaxel Docetaxel Etoposide Darbepoetin alfa (Aranesp) Filgrastim (Neupogen) Fosaprepitant Polysorbate 80 (PS-80) is a synthetic surfa
Slide 10: CINVANTI Demonstrated Bioequivalence to Fosaprepitant and Fewer Treatment-Emergent Adverse Events
CINVANTI™ Demonstrated Bioequivalence to Fosaprepitant and Fewer Treatment-Emergent Adverse Events Within 30 Minutes of Infusion Demonstrated Bioequivalence to Fosaprepitant Fewer TEAEs Within 30 Minutes of Infusion Adverse events with >2% of subjects within 30 min. of infusion Adverse Event CINVANT
Slide 11: CINVANTI Is the First and Only Polysorbate 80-Free IV NK1 Approved for CINV
CINVANTI™ Is the First and Only Polysorbate 80-Free IV NK1 Approved for the Prevention of Both Acute and Delayed CINV CINVANTI™ IV EMEND® IV Varubi® IV aprepitant emulsion fosaprepitant rolapitant Indicated for prevention of both acute and delayed CINV Yes Yes No Can be administered regardless of ch
Slide 12: With CINVANTI, Heron Adds a Second Best-In-Class Therapy to Compete in Branded CINV Market
With CINVANTI™, Heron Adds a Second Best-In-Class Therapy to Compete in a Branded CINV Market with ~3.6M Annual Units Source: IMS TTM Q3’17 Leading Branded CINV Products (Annual Units)
Slide 13: SUSTOL Delivered 28.7K Units in Q3 (8% Growth Vs. Q2)
SUSTOL® Delivered 28.7K Units in Q3 (8% Growth Vs. Q2) SUSTOL Quarterly Unit Performance (Provider Demand) 3.2K 10.3 26.4 28.7 Source: Heron 867 data Net Sales $1.3M $3.6M $8.5M $8.6M
Slide 14: SUSTOL Core Business was Steady, but Growth Slowed in Anticipation of Generic Aloxi
As Expected, SUSTOL® Core Business was Steady, but Growth Slowed in Anticipation of Generic Aloxi® Early Adopter Performance Share Source: Heron 867 data
Slide 15: Market Insights Suggest SUSTOL May Decline Modestly Through the Arbitrage and Grow Thereafter
Unit Sales Market Insights Suggest SUSTOL® May Decline Modestly Through the Arbitrage and Grow Thereafter – Consistent with Aloxi® Analogue Recent Market Insights Practices that are converting to SUSTOL are likely to maintain use1 ~67% of current “dabblers” likely to stop or reduce use of SUSTOL dur
Slide 16: SUSTOL Continues to Outperform Recent CINV New Brand Launches
Despite Expectations of Generic Aloxi®, SUSTOL® Continues to Outperform Recent CINV New Brand Launches CINV New Brand Launches Since 2008 Sources: IMS DDD; Heron actuals (distributor 867 reports); due to data availability, Sancuso data includes actuals for launch months 3-12 and estimates for months
Slide 17: 2017 CINV Franchise Outlook
2017 CINV Franchise Outlook SUSTOL®: We continue to expect core SUSTOL business to hold firm and with possibility of modest decline during arbitrage and growth thereafter Maintain guidance of $25M–$30M in SUSTOL net sales in 2017 Permanent J-code granted by CMS; effective January 1, 2018 CINVANTI™ N
Slide 18: Key Catalysts in Pain & CINV Franchises
Key Catalysts in Pain & CINV Franchises HTX-011 for Postoperative Pain CINVANTI™ for CINV SUSTOL® for CINV Top-line results abdominoplasty NDA submission 2017 net sales guidance: $25M - $30M Phase 2 program in nerve block initiated FDA approval Initiated TKA study (local administration) End-of-Phase
Heron Therapeutics — Investor Presentation (November 2017) on 6ix